Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CΥP2C9 genotype

被引:146
作者
Yasar, Ü
Forslund-Bergengren, C
Tybring, G
Dorado, P
Llerena, A
Sjöqvist, F
Eliasson, E
Dahl, ML
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Dept Med Lab Sci & Technol, Div Clin Pharmacol, Stockholm, Sweden
[2] Univ Extremadura, Sch Med, Dept Pharmacol & Psychiat, Badajoz, Spain
关键词
D O I
10.1067/mcp.2002.121216
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and aim: Losartan is metabolized by polymorphic CYP2C9 to E-3174. Our aim was to evaluate the pharmacokinetics of losartan and E-3174 in relation to the CYP2C9 genotype. Methods: A 50-mg oral dose of losartan was given to 22 Swedish volunteers with different CYP2C9 genotypes. Losartan and E-3174 were analyzed by HPLC in plasma and urine samples collected up to 24 hours after drug intake. Furthermore, losartan and E-3174 were analyzed in 8-hour urine samples collected from 17 Spanish subjects after a single oral dose of 25 mg losartan. Results: The maximum plasma concentration of E-3174 was significantly (P < .05) lower in the CYP2C9*1/*3 (n = 5) and CYP2C9*2/*3 (n = 4) groups compared with the CYP2C9*1/*1 (n = 6) and CYP2C9*1/*2 (n = 3) groups and extremely low in 1 subject with the CYP2C9*3/*3 genotype. The ratio of the total losartan area under the plasma concentration-time curve (AUC) to the total E-3174 AUC (AUC(losartan)/AUC(E-3174)) was higher in the subject with the CYP2C9*3/*3 genotype (30-fold) and also in the CYP2C9*1/*3 and *2/*3 groups (approximately 2- and 3-fold, respectively) compared with the CYP2C9*1/*1 group. The plasma ratios correlated significantly with the 0- to 8-hour urinary losartan/E-3174 ratios. Among the total of 39 subjects, the urinary ratio was significantly higher in subjects with the CYP2C9*1/*3 (n = 10) and *2/*3 (n = 4) genotypes than in those with the CYP2C9*1/*1 genotype (n = 11; P < .01) and approximately 40-fold higher in subjects with the CYP2C9*3/*3 genotype (n = 3). Conclusion: The CYP2C9*3 allele was shown to be associated with decreased formation of E-3174 from losartan. The significant differences between genotypes in plasma and urine losartan/E-3174 ratios and the good correlation between the plasma and urine ratios suggest that the losartan/E-3174 ratio in 0- to 8-hour urine specimens may serve as a phenotyping assay for CYP2C9 activity. Further studies in larger populations will be required to establish this.
引用
收藏
页码:89 / 98
页数:10
相关论文
共 39 条
[1]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[2]  
Aynacioglu AS, 1999, BRIT J CLIN PHARMACO, V48, P409
[3]  
BROCKMOLLER J, 2001, PHARMACOL TOXICOL, V89, P107
[4]   Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype [J].
Chang, M ;
Dahl, ML ;
Tybring, G ;
Gotharson, E ;
Bertilsson, L .
PHARMACOGENETICS, 1995, 5 (06) :358-363
[5]   Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans [J].
Dickmann, LJ ;
Rettie, AE ;
Kneller, MB ;
Kim, RB ;
Wood, AJJ ;
Stein, CM ;
Wilkinson, GR ;
Schwarz, UI .
MOLECULAR PHARMACOLOGY, 2001, 60 (02) :382-387
[6]   Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population [J].
Griese, EU ;
Zanger, UM ;
Brudermanns, U ;
Gaedigk, A ;
Mikus, G ;
Morike, K ;
Stuven, T ;
Eichelbaum, M .
PHARMACOGENETICS, 1998, 8 (01) :15-26
[7]   Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients:: genetic analysis of the CYP2C9 locus [J].
Imai, J ;
Ieiri, I ;
Mamiya, K ;
Miyahara, S ;
Furuumi, H ;
Nanba, E ;
Yamane, M ;
Fukumaki, Y ;
Ninomiya, H ;
Tashiro, N ;
Otsubo, K ;
Higuchi, S .
PHARMACOGENETICS, 2000, 10 (01) :85-89
[8]  
KAMINSKY LS, 1993, MOL PHARMACOL, V43, P234
[9]   Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174 [J].
Kaukonen, KM ;
Olkkola, KT ;
Neuvonen, PJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 53 (06) :445-449
[10]   Effect of fluconazole on the pharmacokinetics of eprosartan and losartan in healthy male volunteers [J].
Kazierad, DJ ;
Martin, DE ;
Blum, RA ;
Tenero, DM ;
Ilson, B ;
Boike, SC ;
Etheredge, R ;
Jorkasky, DK .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (04) :417-425